These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11859990)

  • 1. Measurement of serum CA 19-9 in biliary diseases requires great caution.
    Dorizzi RM; Di Leo A; Guglielmi A; de Manzoni G
    Acta Oncol; 2001; 40(7):877-8. PubMed ID: 11859990
    [No Abstract]   [Full Text] [Related]  

  • 2. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
    Nouts A; Lévy P; Voitot H; Bernades P
    Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease.
    Buffet C; Fourré C; Altman C; Prat F; Fritsch J; Choury A; Briantais MJ; Desgrez A; Etienne JP
    Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):131-4. PubMed ID: 8723416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration of D-dimers in Bile-a Novel Marker of Pancreatic Cancer Enhancing Accuracy of Standard CA19-9 Measurement: Dual Test Hypothesis.
    Durczynski A; Kumor A; Grzelak P; Strzelczyk M; Hogendorf P; Poznanska G; Skulimowski A; Szymanski D; Strzelczyk J
    Pancreas; 2017 Jan; 46(1):e9-e10. PubMed ID: 27763956
    [No Abstract]   [Full Text] [Related]  

  • 7. CA 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test?
    Madonia S; Aragona E; Maisano S; Montalbano L; Olivo M; Rossi F; Restivo G; Cottone M
    Dig Dis Sci; 2007 Apr; 52(4):1125-7. PubMed ID: 17342388
    [No Abstract]   [Full Text] [Related]  

  • 8. Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: does it always imply malignancy?
    Tolliver BA; O'Brien BL
    South Med J; 1997 Jan; 90(1):89-90. PubMed ID: 9003836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CA 19-9 in the differential diagnosis of pancreatic lesions].
    Stintzing S; Herold C; Hahn EG; Boxberger F
    Internist (Berl); 2008 Feb; 49(2):225-7. PubMed ID: 18210015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. False elevation of CA 19-9 levels in a patient with a history of pancreatic cancer.
    Goetz M; Steen PD
    Am J Gastroenterol; 1997 Aug; 92(8):1390-1. PubMed ID: 9260821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CA 242: the search for a valid marker of pancreatic cancer.
    Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
    Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient marked elevation of serum CA 19-9 levels in a patient with acute cholangitis and biliary stent.
    Chintanaboina J; Badari AR; Gopavaram D; Qazi KJ
    South Med J; 2008 Jun; 101(6):661. PubMed ID: 18528223
    [No Abstract]   [Full Text] [Related]  

  • 13. [Differential diagnosis of pancreatic head cancer].
    Kubyshkin VA; Vishnevskiĭ VA; Aĭrapetian AT; Karmazanovskiĭ GG; Kuntsevich GI; Starkov IuG
    Khirurgiia (Mosk); 2000; (11):19-23. PubMed ID: 11220911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of biliary obstruction and cholangitis on serum SPan-1 level].
    Matsumoto S; Muranaka T; Hanada K; Matsuura Y; Oshiumi Y
    Kaku Igaku; 1990 Dec; 27(12):1443-6. PubMed ID: 2290216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV; Edwards R; Ho S; Lau WY; Glazer G
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.
    Goonetilleke KS; Siriwardena AK
    Eur J Surg Oncol; 2007 Apr; 33(3):266-70. PubMed ID: 17097848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection tools for pancreatic cancer.
    Schmidt C
    J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential diagnosis of jaundice by endoscopic retrograde cholangiography.
    Safrany L
    Acta Gastroenterol Belg; 1973 Dec; 36(12):711-24. PubMed ID: 4788303
    [No Abstract]   [Full Text] [Related]  

  • 19. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biliary obstruction induces extremely elevated serum CA 19-9 levels: case report.
    Onal C; Colakoglu T; Ulusan SN; Yapar AF; Kayaselcuk F
    Onkologie; 2012; 35(12):780-2. PubMed ID: 23207625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.